Hørsholm, Denmark, August 21, 2020 – Oncology Enterprise A/S (Nasdaq First North Stockholm: OV.ST) (“OV” or the “Firm”) as we speak broadcasts that it has known as upon World Company Finance (GCF) to put money into the Firm in a directed share concern in accordance with the Firm’s share subscription settlement with GCF. A complete of 5,980,020 shares at a value per share of SEK 1.3420441 is issued to World Company Finance.
The share value is fastened at SEK 1.3420441 per share of nominal DKK 0.05 share and has been calculated as 95% of the each day quantity weighted common value (VWAP) of the Firm’s shares for the 5 (5) consecutive buying and selling days following 11 August 2020, the date of the draw down discover from OV.
The registered share capital of Oncology Enterprise will after the conversion be nominal DKK 9,587,717.55 divided into 191,754,351 shares of nominal DKK 0.05 every.
The funding is the second funding tranche Oncology Enterprise has requested from World Company Finance (New York Metropolis, NY, U.S.). Oncology Enterprise might name upon as much as a complete funding of SEK 50 million in a sequence of tranches, no single tranche might exceed SEK 10 million.
For additional data on the situations and construction of the financing settlement; please, seek advice from the press launch regarding the settlement revealed by Oncology Enterprise on Could 6, 2020.
For additional data, please contact:
Henrik Moltke, CFO
E-mail: [email protected]
Phone +45 21 70 10 49
About Oncology Enterprise A/S
Oncology Enterprise A/S (Nasdaq First North Development Market Stockholm: OV.ST) develops medication for the personalised remedy of most cancers utilizing drug-specific companion diagnostics (cDx) generated by its proprietary drug response predictor know-how, DRP®. The Firm has three high-priority packages: 2X-121 – a PARP inhibitor in Part 2 trials for remedy of ovarian most cancers; IXEMPRA® (Ixabepilone) – an authorized and marketed (U.S.) microtubule inhibitor being superior for Part 2 medical growth (in EU) for remedy of breast most cancers; and Dovitinib – a pan-tyrosine kinase inhibitor (pan-TKI) that’s submit Part three trials, being ready for a U.S. new drug approval (NDA) submitting in renal cell carcinoma (RCC).
In regards to the Drug Response Predictor – DRP® Companion Diagnostic
Oncology Enterprise makes use of its drug-specific DRP® cDx to pick out these sufferers who, by the genetic signature of their most cancers, are discovered to have a excessive chance of responding to the precise drug. The DRP® methodology builds on the comparability of delicate vs. resistant human most cancers cell traces, together with genomic data from cell traces mixed with medical tumor biology and prior medical trial outcomes. The DRP® platform can be utilized in all most cancers varieties and is patented for greater than 70 anti-cancer medication within the U.S.
Comply with us on social media:
Study extra at oncologyventure.com.
DRP® is a registered trademark of Oncology Enterprise A/S.
This announcement contains forward-looking statements that contain dangers, uncertainties and different components, lots of that are exterior of OV’s management and which might trigger precise outcomes to vary materially from the outcomes mentioned within the forward-looking statements. Ahead-looking statements embrace statements regarding OV’s plans, aims, objectives, future occasions, efficiency and/or different data that’s not historic data. All such forward-looking statements are expressly certified by these cautionary statements and some other cautionary statements which can accompany the forward-looking statements. OV undertakes no obligation to publicly replace or revise forward-looking statements to mirror subsequent occasions or circumstances after the date made, besides as required by regulation.
Svensk Kapitalmarknadsgranskning AB, E-mail: [email protected] Tel: +46 11 32 30 732
This data is data that Oncology Enterprise A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The data was submitted for publication on August 21, 2020.